Q2
ABOS — Q2 2026 Financial Report Analysis
Acumen’s Q2 2026 net loss narrowed to $32.7M as Alzheimer’s trial manufacturing costs fell, but $110.2M of cash lasts only into early 2027, triggering a going-concern warning ahead of late-2026 ALTITUDE-AD results.